Chengkai Wu

No. 55 Zhenhai Road, Xiamenwuuker@163.com

A researcher specializing in chronic disease epidemiology, metabolic disorders, and artificial intelligence-assisted disease prediction. His research focuses on chronic kidney disease (CKD), hyperuricemia, metabolic syndrome, obesity-related metabolic abnormalities, and non-alcoholic fatty liver disease. He has extensive experience in population-based cohort studies, particularly using large-scale datasets such as the UK Biobank, to investigate disease risk factors, clinical outcomes, and prognostic indicators. Research integrates epidemiological approaches with machine learning and multimodal data analysis to identify early diagnostic markers and improve risk stratification. His work has been published in peer-reviewed journals, including *Advanced Science*, *Frontiers in Nutrition*, *BMC Nephrology*, and *BMC Gastroenterology*. His broader research interests include the interplay between lifestyle factors, metabolic health, and chronic disease progression, with an emphasis on translating epidemiological findings into precision prevention and personalized healthcare.

PublicationsPublications

  1. Xu, J., Liu, Y., Zhang, H., Yuan, Z., Sheng, Y., Wang, X., Liu, H., Zhong, F., Zhang, H., Xiong, H., Chen, X., Zhang, Q., Liu, J., Cai, L., Huang, Q., Yue, H., Huang, L., Zhu, N., Yuan, Y., … Wu, C. (2026). Mitochondrial regulation of tumor-associated macrophage function. Frontiers in Immunology, 17, 1971517–1971517. https://doi.org/10.3389/fimmu.2026.1971517
    CiteBibTeX RIS CSL-JSON
    PubMed
    Abstract

    Tumor-associated macrophages (TAMs) adapt to hypoxia, nutrient competition, lipid accumulation, and anticancer treatment. Mitochondria contribute to this adaptation through energy metabolism, redox signaling, mitochondrial DNA (mtDNA) sensing, and metabolite-dependent regulation of gene expression. This Review examines mitochondrial dynamics, mitophagy, proteostasis, respiratory remodeling, and lipid-droplet interactions, distinguishing direct TAM evidence from findings in other experimental systems. Tumor studies link these processes to IL-12 and IL-10 production, interferon responses, antigen presentation, and lymphocyte recruitment, with effects that vary by pathway and macrophage state. These findings do not establish a single optimal level of mitochondrial quality control. We discuss how macrophage lineage, spatial niche, and treatment exposure may influence the response to mitochondrial interventions. Therapeutic development will require causal validation in defined TAM populations, selective delivery, and measurements of immune function alongside mitochondrial changes. Evidence in human TAMs and direct studies of organelle contacts remain limited. Somatic mtDNA variation is considered separately from altered gene expression and DNA release, with lineage-tracing evidence distinguished from functional causation.

Updated Nov 21, 2026 · living CV, updates automatically

SubscribeAdd this feed URL to your RSS reader: https://sigmacv.org/p/chengkai-wu-ffa8192ae35cba567575/feed.xml

Save these publications to a reference manager (Zotero, Mendeley…) — your browser connector will detect them.

Made with SigmaCV